サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411541

がん遺伝子治療市場：治療法、適応症、用途別-2024-2030年の世界予測

Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Gene Transfer, Oncolytic Virotherapy), Indication (Breast Cancer, Liver Cancer, Lung Cancer), End-Use - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
がん遺伝子治療市場：治療法、適応症、用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん遺伝子治療市場規模は2023年に22億米ドルと推計され、2024年には27億5,000万米ドルに達し、CAGR 20.22%で2030年には79億9,000万米ドルに達すると予測されます。

がん遺伝子治療の世界市場

主な市場の統計
基準年[2023］ 22億米ドル
予測年[2024］ 27億5,000万米ドル
予測年 [2030] 79億9,000万米ドル
CAGR（%） 20.22%
がん遺伝子治療 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはがん遺伝子治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、がん遺伝子治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-がん遺伝子治療市場の市場規模および予測は？

2-がん遺伝子治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-がん遺伝子治療市場における技術動向と規制の枠組みは？

4-がん遺伝子治療市場における主要ベンダーの市場シェアは？

5-がん遺伝子治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • がんの蔓延に対処するための治療選択肢の必要性
      • がん調査を促進するための研究開発活動の強化
      • がんの治療法や遺伝子治療の開発に対する政府の支援
    • 抑制要因
      • 有害な免疫反応と製品のリコールのリスク
    • 機会
      • 遺伝子治療がんセンターを世界中に拡大
      • 細胞治療と遺伝子治療を加速するためのAIとMLの活用
    • 課題
      • 遺伝子治療の安全性に関する規制上の考慮事項
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 がん遺伝子治療市場セラピー別

  • 遺伝子誘導免疫療法
  • 遺伝子導入
  • 腫瘍溶解性ウイルス療法

第7章 がん遺伝子治療市場適応症別

  • 乳がん
  • 肝臓がん
  • 肺がん
  • 卵巣がん
  • 膵臓がん
  • 前立腺がん

第8章 がん遺伝子治療市場：最終用途別

  • バイオ医薬品企業
  • 診断センター
  • 腫瘍学調査

第9章 南北アメリカのがん遺伝子治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のがん遺伝子治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのがん遺伝子治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abeona Therapeutics Inc.
    • Achieve Life Sciences, Inc.
    • Adaptimmune Therapeutics PLC
    • Alaunos Therapeutics Inc.
    • Amgen, Inc.
    • Bayer AG
    • Biogen Inc.
    • Bluebird Bio Inc.
    • Bristol-Myers Squibb Company
    • Candel Therapeutics
    • Elevate Bio Inc.
    • Genelux Corporation
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Inc.
    • ImmunityBio, Inc.
    • Merck KGaA
    • Precigen, Inc.
    • Sarepta Therapeutics, Inc.
    • Shanghai Sunway Biotech Co., Ltd.
    • Sibiono GeneTech Co. Ltd.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. CANCER GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. CANCER GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER GENE THERAPY MARKET DYNAMICS
  • FIGURE 7. CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 8. CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER GENE THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER GENE THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER GENE THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 148. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. CANCER GENE THERAPY MARKET LICENSE & PRICING
目次
Product Code: MRR-B1685377A71B

[194 Pages Report] The Cancer Gene Therapy Market size was estimated at USD 2.20 billion in 2023 and expected to reach USD 2.75 billion in 2024, at a CAGR 20.22% to reach USD 7.99 billion by 2030.

Global Cancer Gene Therapy Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.20 billion
Estimated Year [2024] USD 2.75 billion
Forecast Year [2030] USD 7.99 billion
CAGR (%) 20.22%
Cancer Gene Therapy Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Gene Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Gene Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Achieve Life Sciences, Inc., Adaptimmune Therapeutics PLC, Alaunos Therapeutics Inc., Amgen, Inc., Bayer AG, Biogen Inc., Bluebird Bio Inc., Bristol-Myers Squibb Company, Candel Therapeutics, Elevate Bio Inc., Genelux Corporation, Gilead Sciences, Inc., GlaxoSmithKline Inc., ImmunityBio, Inc., Merck KGaA, Precigen, Inc., Sarepta Therapeutics, Inc., Shanghai Sunway Biotech Co., Ltd., and Sibiono GeneTech Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapy
    • Gene Induced Immunotherapy
    • Gene Transfer
    • Oncolytic Virotherapy
  • Indication
    • Breast Cancer
    • Liver Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
  • End-Use
    • Biopharmaceutical Companies
    • Diagnostic Centers
    • Oncology Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Gene Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Gene Therapy Market?

3. What are the technology trends and regulatory frameworks in the Cancer Gene Therapy Market?

4. What is the market share of the leading vendors in the Cancer Gene Therapy Market?

5. Which modes and strategic moves are suitable for entering the Cancer Gene Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Gene Therapy Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for treatment options to tackle the growing prevalence of cancers
      • 5.1.1.2. Increasing R&D activities to stimulate cancer research
      • 5.1.1.3. Government support for the development of cancer treatment methods and gene therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of adverse immune reaction and recall of products
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of gene therapy cancer centers worldwide
      • 5.1.3.2. Utilization of AI and ML to accelerate cell and gene therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory considerations concerning the safety of gene therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Cancer Gene Therapy Market, by Therapy

  • 6.1. Introduction
  • 6.2. Gene Induced Immunotherapy
  • 6.3. Gene Transfer
  • 6.4. Oncolytic Virotherapy

7. Cancer Gene Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Liver Cancer
  • 7.4. Lung Cancer
  • 7.5. Ovarian Cancer
  • 7.6. Pancreatic Cancer
  • 7.7. Prostate Cancer

8. Cancer Gene Therapy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biopharmaceutical Companies
  • 8.3. Diagnostic Centers
  • 8.4. Oncology Research Institutes

9. Americas Cancer Gene Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abeona Therapeutics Inc.
    • 13.1.2. Achieve Life Sciences, Inc.
    • 13.1.3. Adaptimmune Therapeutics PLC
    • 13.1.4. Alaunos Therapeutics Inc.
    • 13.1.5. Amgen, Inc.
    • 13.1.6. Bayer AG
    • 13.1.7. Biogen Inc.
    • 13.1.8. Bluebird Bio Inc.
    • 13.1.9. Bristol-Myers Squibb Company
    • 13.1.10. Candel Therapeutics
    • 13.1.11. Elevate Bio Inc.
    • 13.1.12. Genelux Corporation
    • 13.1.13. Gilead Sciences, Inc.
    • 13.1.14. GlaxoSmithKline Inc.
    • 13.1.15. ImmunityBio, Inc.
    • 13.1.16. Merck KGaA
    • 13.1.17. Precigen, Inc.
    • 13.1.18. Sarepta Therapeutics, Inc.
    • 13.1.19. Shanghai Sunway Biotech Co., Ltd.
    • 13.1.20. Sibiono GeneTech Co. Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing